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Abstract
Background: Mitochondria contribute to the dynamics of cellular metabolism, the production of reactive oxygen species,
and apoptotic pathways. Consequently, mitochondrial function has been hypothesized to influence functional decline and
vulnerability to disease in later life. Mitochondrial genetic variation may contribute to altered susceptibility to the frailty
syndrome in older adults.
Methodology/Principal Findings: To assess potential mitochondrial genetic contributions to the likelihood of frailty,
mitochondrial DNA (mtDNA) variation was compared in frail and non-frail older adults. Associations of selected SNPs with a
muscle strength phenotype were also explored. Participants were selected from the Cardiovascular Health Study (CHS), a
population-based observational study (1989–1990, 1992–1993). At baseline, frailty was identified as the presence of three or
more of five indicators (weakness, slowness, shrinking, low physical activity, and exhaustion). mtDNA variation was assessed
in a pilot study, including 315 individuals selected as extremes of the frailty phenotype, using an oligonucleotide
sequencing microarray based on the Revised Cambridge Reference Sequence. Three mtDNA SNPs were statistically
significantly associated with frailty across all pilot participants or in sex-stratified comparisons: mt146, mt204, and mt228. In
addition to pilot participants, 4,459 additional men and women with frailty classifications, and an overlapping subset of
4,453 individuals with grip strength measurements, were included in the study population genotyped at mt204 and mt228.
In the study population, the mt204 C allele was associated with greater likelihood of frailty (adjusted odds ratio=2.04, 95%
CI=1.07–3.60, p=0.020) and lower grip strength (adjusted coefficient=22.04, 95% CI=23.33– 20.74, p=0.002).
Conclusions: This study supports a role for mitochondrial genetic variation in the frailty syndrome and later life muscle
strength, demonstrating the importance of the mitochondrial genome in complex geriatric phenotypes.
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Introduction
Mitochondria are a principle contributor to cellular metabolism
and produce much of the chemical energy required by cells [1–3].
Mitochondria are also integral to some apoptotic processes and are
a major production site of reactive oxygen species (ROS) which
have both essential and deleterious functions within cells [3–7].
Mitochondrial capacity for ATP production and the efficiency of
this production are determinants of cellular metabolism, and are
thus integral to the dynamics of energy supply and influence
metabolic rate of the body on whole [8]. Mitochondria are potential
contributors to reductions in the ability to modify resting metabolic
rate in response to stressors, and it has been hypothesized that such
losses of metabolic plasticity may lead to dysregulation of
homeostatic balance and subsequent declines in health [9]. Due
to these diverse functions, age-related changes in mitochondria as
well as variation in the mitochondrial DNA (mtDNA) have been
hypothesized to play a role in degenerative and senescent processes
and ultimately contribute to increases in late life vulnerability to
chronic disease states, and functional decline. Mitochondrial
variation is also hypothesized to influence frailty, a syndrome of
decreased reserve and resilience characterized by multi-systemic
declines [10,11]. Indeed, variants in mtDNA have been associated
with an increased risk for many chronic diseases and conditions
common in older adults including aspects of cardiovascular disease,
diabetes, dementias, hearing loss, and cancers [3,12–16].
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11069We hypothesized that the accumulation of environmental
exposures across the life course may alter the magnitude of the
effect of mtDNA variants on mitochondrial pathways or that
inherited patterns of general inefficiency may manifest as
observable deficits in later life when accumulated damage is no
longer compensated for by other systems increasing susceptibility
to the frailty syndrome. In addition, given that the impact of
mitochondrial dysfunction may be more pronounced in metabol-
ically active skeletal muscle tissue we further explored a possible
intermediate phenotype, grip strength, in order to gain insight into
the potential paths linking mtDNA to the frailty phenotype.
Methods
Ethics Statement
CHS protocols were approved by each field center’s institu-
tional review board; all participants provided written informed
consent.
Study Design
The study population and a small pilot group were selected
from the Cardiovascular Health Study (CHS). CHS is a
population-based prospective cohort study of the causes of
cardiovascular disease in community dwelling adults aged 65
and older; CHS study design, population selection, and protocols
have been previously described [17]. Briefly, potential study
participants were recruited based upon Medicare eligibility data
from four areas: Forsyth County, NC, Sacramento County, CA,
Washington County, MD, and Pittsburgh, PA. 5,201 participants
were initially enrolled; to improve cohort diversity an additional
687 African-Americans were later recruited. At baseline, June
1989 – June 1990 and November 1992 – June 1993, CHS
participants completed an interview and examination that
ascertained detailed demographic, health history, and health
behavior information as well as clinical and laboratory measure-
ments [17]. Demographic information and anthropometric
measurements used for our analyses, including age, sex, race,
and BMI, were obtained from CHS baseline interview and
examination data. Adjudicated diagnosis of coronary heart disease
(CHD), congestive heart failure (CHF), and diabetes mellitus were
also drawn from the CHS baseline evaluation [17]. Frail
individuals were identified by the presence of three or more of
the following previously validated criteria: shrinking, slow walking
speed, weakness, self-reported exhaustion, and low physical
activity [10,11]. Isometric grip strength was measured using a
Jamar hand-held dynamometer: the strength measure represents
the mean of three attempts with the dominant hand [10].
Weakness was defined as a strength measure below the 20th
percentile of sex and BMI stratified strength distributions [10].
The pilot study of 154 frail (mean age=75.00, s.d.=4.45) and
161 older robust (mean age=81.35 s.d.=3.16) individuals was
selected from CHS participants who provided consent for genetic
studies. In an attempt to maximize the genetic difference between
the two groups the pilot participants were selected from the
youngest frail and oldest robust participants. We further restricted
selection to self-identified whites, due to the limited number of frail
blacks in CHS, and matched on sex, resulting in ,70% females in
the pilot group. Individuals with Parkinson’s disease, as identified
by self-report or medication use, were not eligible for the pilot
study, individuals who used Alzheimer’s disease related medica-
tions, anti-depressants, had a Mini-Mental State Exam score less
than 18, BMI greater than 40, or adjudicated history of stroke
were also ineligible. ‘‘Robust’’ individuals in the pilot group were
the oldest eligible non-frail individuals. All individuals in the CHS
study who provided consent for genetic studies were eligible for the
full study population. From the 5,077 additional CHS participants
with available DNA, but not included in the pilot study, 31
individuals reporting a race/ethnicity other than white or black
were excluded. An additional 515 individuals were excluded for
indicators of disease (as above) and 96 were excluded for BMI.40.
The frailty status of 7 remaining participants was not classified.
The final combined population for frailty analyses included 4,459
participants not genotyped in the pilot group plus the 315 pilot
participants. Exploratory grip strength analyses excluded individ-
uals based upon the same disease-related criteria but included
some individuals that lacked frailty status classification. Partici-
pants were excluded that were missing BMI data or had grip
strength recorded as ,0k go r.80 kg (n=317). The final grip
strength analyses included 4,453 participants.
Genotyping
In the pilot study, variants in mtDNA obtained from peripheral
lymphocytes were characterized using an oligonucleotide sequenc-
ing microarray with probes based upon the Revised Cambridge
Reference Sequence (rCRS [NC_012920]): the Human Mito-
chondrial Resequencing Array 2.0 (Affymetrix, Santa Clara, CA)
[18]. Grid-alignment and genotype calls were assigned using RA
Tools Ver1.0.5 (http://www.dpgp.org/RA/ra.htm) based on the
ABACUS algorithm under a model that assumes a completely
haploid genome (i.e. no appreciable levels of heteroplasmy) [19].
An average call rate of 98.6% (range 97.2% to 98.9%) was
observed. SNPs were detected at 899 sites, and 209 SNPs with
minor allele frequencies (MAF) greater than 1% were included in
this analysis.
Individual SNPs selected for follow-up, after demonstrating
nominal statistical significance (p,0.05) in pilot analyses, were
genotyped with TaqMan assays (Applied Biosystems, Foster City,
CA) in all 5,392 CHS participants with genetic consent. Raw data
were analyzed using a model that may detect potential hetero-
plasmy. Genotyping at mt204 was 89.1% complete, and mt228
was 92.0% complete. Frequency of potential heteroplasmy among
called genotypes was .003 and ,.001 respectively. The concor-
dance between resequencing array and confirmatory TaqMan
assay calls was 99.43%. In analyses of mt204 and mt228 using the
full population, resequencing array and TaqMan genotypes were
combined to minimize missing genotypes. Pilot participants with
inconsistent calls across methods were assigned ‘no call’ at the
SNP, which resulted in 2 missing genotypes at mt204 and 1 at
mt228. Participants with calls indicating potential heteroplasmy
were also assigned ‘no call’.
Statistical Analysis
Student’s t-tests with unequal variance and Fisher’s exact x
2
tests were used to describe the distribution of non-genetic variables
of interest across frail and robust individuals among pilot
participants and across allele groups in the study population. In
the pilot study Fisher’s exact x
2 tests were used to detect whether
the proportion of frail and robust individuals who possessed the
minor allele at each of the 209 mtSNPs with MAF .0.01 differed
from expectation. The x
2 tests were calculated across all
participants genotyped at a SNP as well as in sex-stratified groups.
In the study population, cross-sectional frailty analyses were
stratified by race and sex. Fisher’s exact x
2 tests were used to
compare the proportion of individuals with each allele at selected
SNPs. Logistic regression models were used to compare the odds
of frailty among allele groups adjusted for age, sex, and/or race.
Exploratory cross-sectional grip strength analyses included com-
parison of the strength measurement across alleles using t-tests
mtDNA SNPs and Frailty
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between grip strength and allele was modeled using linear
regression. Models were adjusted for age, (age270)
+, BMI,
BMI
2, race and/or sex. Grip strength comparisons were repeated
after excluding frail participants. Sensitivity analyses compared
measures of association when individuals with potential hetero-
plasmy were included in different allele groups. All analyses were
performed using R, version 2.8.1 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Association of mtDNA variation with frailty
To assess the potential for a mitochondrial genetic contribution
to frailty, common variants in mtDNA, identified using oligonu-
cleotide resquencing arrays, were compared among frail and non-
frail individuals in a pilot study. This 315 person group was
selected from CHS based upon demographic and disease-related
characteristics, focusing on the youngest frail and oldest robust
individuals, in an attempt to maximize the genetic difference
between the two groups. The pilot group was further restricted to
self-identified whites and matched on the proportion of women in
the frail and non-frail group. As expected based upon the pilot
study selection criteria, the mean age of individuals in the non-frail
group (81.35 yrs, s.d.=3.16) was substantially greater than that of
the frail group (75.00 yrs, s.d.=4.45). Further, the frail partici-
pants demonstrated a larger chronic disease burden than non-frail
pilot participants with approximately two to four times greater
prevalence of diabetes mellitus, coronary heart disease, and
congestive heart failure (Table 1).
When comparing SNP differences between frail and non-frail
groups in the pilot study, the most statistically significant p-value
achieved, 0.006, was observed at a SNP in the D-loop, mt204
(Table S1). A disproportionate number of frail individuals (7/141,
5%) possessed the minor allele (C) at this position compared to the
non-frail individuals (0/151). In sex-stratified comparisons the
lowest p-values were also observed at SNPs in the D-loop: in men
at mt146 (p=0.003) and in women at mt228 (p=0.035) (Table
S1). The A allele at position 228 was observed in 8/111 (7.2%)
frail women but in only 1/110 (0.9%) non-frail women.
The three SNPs that were statistically significant (p,0.05) in the
overall or sex-stratified analyses of pilot resequencing array
genotypes were selected as candidates for genotyping in the
remaining CHS samples; however assay design failed for mt146,
which was subsequently dropped from all further analyses. As
shown in Table 2, 87 of 3,708 eligible white individuals (2.3%) are
carriers of the C allele at mt204. At mt228, The A allele was
present in 211 out of 3,821 (5.5%) white individuals (Table S2).
The distributions of demographic and disease-related variables
were similar across allele groups at mt204 and mt228 in non-pilot
participants (Table 2, Table S2).
To assess the relationship of variation at mt204 and mt228 with
frailty, trends in the frequency of the minor allele at each
candidate SNP were observed and logistic regression models were
evaluated. While not statistically significant, the direction of the
odds ratio for frailty in the group of all CHS participants
identifying as white was consistent with pilot data for mt204: in a
logistic regression model adjusted for age and sex the odds of
frailty were 1.75 (95% CI=0.74–3.61, p=0.164) times greater
among the group with the C allele than those with the T allele.
The non-pilot white participant group includes few frail
individuals however adjusted models still indicated a small positive
association between the C allele and frailty (Table 3). In the group
of participants identifying as black, none of whom were part of the
pilot study, a similar trend was observed, odds ratio: 2.33 (95%
CI=0.82–5.74, p=0.082). Given the consistent directions of
association across race/ethnicity stratified groups, combined
models assessing mt204 allele were evaluated. The odds of frailty
were statistically significantly greater among all participants with
the C allele than those with the T allele after adjustment for age,
sex, and race, odds ratio: 2.04 (95% CI=1.07–3.60, p=0.020). In
sex-stratified groupings a stronger association between the minor
allele and frailty was observed among men: 3.83 (95% CI=1.48–
8.77, p=0.003), than among women: 1.33 (95% CI=0.53–2.86,
p=0.503). Using a model incorporating a sex by allele interaction
term, we observed a 2.93-fold (95% CI=0.87–9.93) increased risk
in men relative to women, although this result did not achieve
statistical significance (p=0.079). A consistent association between
the mt228 A allele and frailty was not observed in the study
population (Table S3). Substantial differences in these associations
were not observed in sensitivity analyses including potentially
heteroplasmic participants.
Association of mt204 with grip strength
Weakness is a component of the frailty syndrome that may
relate closely to mitochondrial variation because it is partially
Table 1. Distribution of selected characteristics among all CHS white and black participants with frailty classification (n=5275) as
well as in the pilot population across frailty status.
Characteristic White Pilot Black
Non-frail Frail p* Non-frail Frail p Non-frail Frail p
(n=4223) (n=262) (n=161) (n=154) (n=688) (n=102)
Age, mean 6 SD 72.43±5.37 77.36±6.36 ,.001 81.35±3.16 75.00±4.45 ,.001 72.05±5.09 75.44±6.76 ,.001
Female, n (%) 2377 (56.3) 174 (66.4) .001 111 (68.9) 112 (72.7) .536 425 (61.8) 76 (74.5) .015
Body mass index, mean 6 SD{ 26.3264.33 26.5265.61 .570 24.98±3.65 26.28±4.75 .007 28.6165.25 29.0067.01 .595
Diabetes mellitus, n (%){ 571 (13.6) 60 (23.1) ,.001 13 (8.1) 38 (24.8) ,.001 161 (24.2) 29 (30.2) .209
Coronary heart disease, n (%) 776 (18.4) 83 (31.7) ,.001 28 (17.4) 52 (33.8) .001 127 (18.5) 24 (23.5) .226
Congestive heart failure, n (%) 138 (3.3) 37 (14.1) ,.001 6 (3.7) 26 (16.9) ,.001 29 (4.2) 14 (13.7) ,.001
*t-test with unequal variance for comparison of continuous characteristics across pilot population groups, Fisher’s exact x
2 for categorical comparisons.
{missing BMI for some participants: white nnon-frail=4212, nfrail=262; black nnon-frail=686, nfrail=101.
{missing diabetes mellitus status for some participants: white nnon-frail=4199, nfrail=260; pilot nnon-frail=160, nfrail=153, black nnon-frail=665,n frail=96.
doi:10.1371/journal.pone.0011069.t001
mtDNA SNPs and Frailty
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active tissue. Associations of mt204 allele with grip strength were
assessed using multiple linear regression models. Lower mean grip
strength was observed in groups with the mt204 C allele,
consistent with the effect of the C allele on frailty. In multivariate
linear regression models adjusting for age, (age270)
+, sex, BMI
and BMI
2, the C allele was associated with an approximately two
kilogram mean reduction in strength: 22.04 (95% CI=23.33,
20.74, p=0.002) (Table 4). In sex-stratified models, the C allele
was associated with a greater reduction in strength among men:
23.48 kg (95% CI=25.94 – 21.02, p=0.006), than among
women: 21.13 kg (95% CI=22.50–0.24, p=0.105) (p for
interaction=0.075).
To test whether the association with grip strength was driven by
the association with frailty, we assessed grip strength after
excluding frail participants. The inverse relationship between the
C allele and grip strength persisted after excluding frail
participants, indicating that the mt204 association with grip
strength was not solely a product of its association with frailty
(Table S4). To test the reverse hypothesis, that the association with
grip strength may be driving the association with frailty, grip
strength was introduced into logistic regression models for frailty.
The mt204 odds ratio in most models was attenuated but
remained positive (Table S5). Further, while the mt204 C allele
was not statistically significantly associated with four other
phenotypes that help define the frailty syndrome, marginal
positive trends were observed for three of the criteria (Table S6).
Discussion
Given the role of mitochondria in decreased metabolism and
increased generation of ROS with aging, there is a strong a priori
argument that mtDNA variation may contribute to global losses in
metabolic plasticity leading to the decreased resilience that is a
hallmark of the frailty phenotype. In the present study, analyses of
genotypes representing the entire mtDNA obtained through
evaluation of a resequencing array under a haploid model in a
pilot study of frail and robust individuals generated several
promising SNPs. Through follow up genotyping of selected
candidates in the entire CHS cohort, we identified mt204 to be
associated with frailty. Though less pronounced than in the pilot
study, consistently positive associations between the C allele and
frailty were observed across all study population groups including
participants identifying as black, a group that does not overlap the
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Table 3. Odds ratios estimating the association of frailty with
the C allele at mt204 in the CHS populations observed in
stratified multivariate logistic regression models adjusted for
age, sex and/or race.
Group
Odds ratio (95%
confidence interval) p
Race/ethnicity
strata
White All (n=3708) 1.75 (0.74, 3.61) .164
Non-pilot
(n=3408)
1.11 (0.15, 4.70) .904
Black (n=570) 2.33 (0.82, 5.74) .082
Combined
(n=4278)
2.04 (1.07, 3.60) .020
Sex strata Female (n=2445) 1.33 (0.53, 2.86) .503
Male (n=1833) 3.83 (1.48, 8.77) .003
doi:10.1371/journal.pone.0011069.t003
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stratification of the population by sex: the odds of frailty among
men with the C allele were three times those with the T allele.
Further, the absence of variation in the distribution of diabetes
mellitus, coronary heart disease, and congestive heart failure by
mt204 allele in the full study population suggests that the observed
associations with frailty may not be a consequence of an
association with chronic disease. Subsequently, an association
between mt204 and grip strength was explored, not only because
of the contribution of grip strength to frailty assessment, but also
because of the dependence of skeletal muscle on metabolic
processes. Again, the observed association was more pronounced
in males, but was consistent across the entire CHS population and
remained even after excluding frail individuals to minimize the
potential for bias due to initial selection methods. The presence of
an association in the absence of frail participants strongly suggests
that the mt204 association with grip strength is not a consequence
of its association with frailty. Models for frailty incorporating grip
strength and models for other frailty related variables (uninten-
tional weight loss, exhaustion, and low physical activity level)
suggest that general skeletal muscle strength, captured here by grip
strength, may influence other components of the syndrome, or
mt204 may broadly contribute to frailty in a manner that is most
apparent in the weakness component.
While mt204 is not in a protein coding region, its location
suggests plausible mechanisms for influencing frailty and grip
strength. mt204 is within hypervariable segment 2 and has been
previously documented as a variant in phylogenetic analyses of the
mitochondrial DNA sequence, but is not unique to a single
haplogroup [20,21]. The SNP is also located within the D-loop of
the mtDNA control region [20]. mtDNA control region SNPs
have been both positively and negatively associated with longevity
[22] and mt16189, also a control region variant, has been
associated with endometrial cancer and diabetes risk [23,24].
mt204 is located within the heavy strand origin of replication [25],
and thus variation at this SNP may effect the efficiency of mtDNA
replication; autosomal genes have been previously linked to
mtDNA replication disorders that include muscle myopathy
phenotypes [26]. Other SNPs identified in the pilot population,
mt146 and mt228, are also located in this region.
While pathways involving variation at mt204 are plausible, it is
also possible that the observed associations are due to chance or an
unrecognized consequence of population selection criteria.
Validation of the mt204 findings in different populations as well
as exploration of intermediate phenotypes is necessary. Addition-
ally, several limitations of the present study should be noted. The
small size of the pilot study limits statistical power as well as the
ability to characterize the effects of less common genetic variants:
it is possible that selected candidates do not represent the only
mtDNA variants with a potential influence on frailty. In this study
we have taken an approach focusing on inherited variation (as
measured in DNA isolated from pooled lymphocytes) as opposed
to somatic changes, and we are not able to assess the variants of
interest in additional tissue types. In our exploration of grip
strength we were unable to fully characterize other influences on
muscle strength such as muscle mass and neuromuscular control.
Finally, the majority of mitochondrial functional and structural
genes are located within the autosomal genome: describing
variation in these genes may be critical to fully characterizing
mitochondrial contributions to frailty. Despite these limitations, we
observed statistically significant association between variation in
the mitochondrial genome and frailty. Variation in mitochondrial
function may lead to homeostatic dysregulation that may be
central to this complex geriatric phenotype. The results of this
investigation support a role for mitochondrial genetic variation in
the frailty syndrome and later life muscle strength.
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Group Model 1* Model 2{
Coefficient (95% confidence interval) p
Race/ethnicity strata White (n=3435) 21.60 (23.10, 20.11) .035 21.63 (23.12, 20.14) .032
Black (n=558) 23.11 (25.85, 20.37) .027 23.26 (25.99, 20.54) .019
Combined (n=3993) 21.80 (23.10, 20.50) .006 22.04 (23.33, 20.74) .002
Sex strata Female (n=2274) 20.87 (22.26, 0.51) .217 21.13 (22.50, 0.24) .105
Male (n=1719) 23.31 (25.77, 20.85) .008 23.48 (25.94, 21.02) .006
*Adjusted for age, (age270)
+, and sex.
{Adjusted for age, (age270)
+, BMI, BMI
2, male sex and/or black race.
doi:10.1371/journal.pone.0011069.t004
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